MDR Tuberculosis Treatment

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2022 Feb 25

PMID 35208510

Authors

Juan Espinosa-Pereiro

Adrian Sanchez-Montalva

Maria Luisa Aznar

Maria Espiau

Affiliations

Soon will be listed here.

Abstract

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic. Over the last few years, there have been promising pharmacological advances in the paradigm of MDR TB treatment: new and repurposed drugs have shown excellent bactericidal and sterilizing activity against and several all-oral short regimens to treat MDR TB have shown promising results. The purpose of this comprehensive review is to summarize the most important drugs currently used to treat MDR TB, the recommended regimens to treat MDR TB, and we also summarize new insights into the treatment of patients with MDR TB.

Citing Articles

Association Between Diabetes Mellitus-Tuberculosis and the Generation of Drug Resistance.

Cornejo-Baez A, Zenteno-Cuevas R, Luna-Herrera J Microorganisms. 2025; 12(12.

PMID: 39770852 PMC: 11728438. DOI: 10.3390/microorganisms12122649.

Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024.

Wei S, He C, Xie X, Zhang A, Tang S, Li S Front Pharmacol. 2024; 15:1491921.

PMID: 39726777 PMC: 11669847. DOI: 10.3389/fphar.2024.1491921.

Sodium, Potassium-Adenosine Triphosphatase as a Potential Target of the Anti-Tuberculosis Agents, Clofazimine and Bedaquiline.

Mmakola K, Balmith M, Steel H, Said M, Potjo M, van der Mescht M Int J Mol Sci. 2024; 25(23).

PMID: 39684733 PMC: 11640857. DOI: 10.3390/ijms252313022.

Sputum culture contamination and associated characteristics in a diagnostic clinical trial, Papua New Guinea.

Tenakanai N, Banamu J, Lin Y, Walsh D, Simbil R, Globan M Public Health Action. 2024; 14(4):152-157.

PMID: 39618834 PMC: 11604157. DOI: 10.5588/pha.24.0029.

The Biological Characteristics of Phage Henu3 and the Fitness Cost Associated with Its Resistant Strains.

Li X, Xu J, Wang Y, Gomaa S, Zhao H, Teng T Int J Mol Sci. 2024; 25(17).

PMID: 39273250 PMC: 11394830. DOI: 10.3390/ijms25179301.

References

Ismail N, Omar S, Joseph L, Govender N, Blows L, Ismail F . Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine. 2018; 28:136-142. PMC: 5835552. DOI: 10.1016/j.ebiom.2018.01.005. View

Dheda K, Gumbo T, Lange C, Horsburgh Jr C, Furin J . Pan-tuberculosis regimens: an argument against. Lancet Respir Med. 2018; 6(4):240-242. DOI: 10.1016/S2213-2600(18)30097-3. View

ODonnell M, Padayatchi N, Daftary A, Orrell C, Dooley K, Amico K . Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. Lancet HIV. 2019; 6(3):e201-e204. PMC: 7155388. DOI: 10.1016/S2352-3018(19)30035-9. View

Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W . Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010; 55(1):355-60. PMC: 3019671. DOI: 10.1128/AAC.01030-10. View

Bloemberg G, Keller P, Stucki D, Stuckia D, Trauner A, Borrell S . Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med. 2015; 373(20):1986-8. PMC: 4681277. DOI: 10.1056/NEJMc1505196. View

Falzon D, Schunemann H, Harausz E, Gonzalez-Angulo L, Lienhardt C, Jaramillo E . World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017; 49(3). PMC: 5399349. DOI: 10.1183/13993003.02308-2016. View

Boyer E, Shannon M . The serotonin syndrome. N Engl J Med. 2005; 352(11):1112-20. DOI: 10.1056/NEJMra041867. View

Xu C, Kreiswirth B, Sreevatsan S, Musser J, Drlica K . Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis. 1996; 174(5):1127-30. DOI: 10.1093/infdis/174.5.1127. View

Akbergenov R, Shcherbakov D, Matt T, Duscha S, Meyer M, Wilson D . Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob Agents Chemother. 2011; 55(10):4712-7. PMC: 3187005. DOI: 10.1128/AAC.00628-11. View

10.

McGee B, Dietze R, Hadad D, Molino L, Maciel E, Boom W . Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2009; 53(9):3981-4. PMC: 2737850. DOI: 10.1128/AAC.01378-08. View

11.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T . Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2012; 41(6):1393-400. PMC: 3669462. DOI: 10.1183/09031936.00125812. View

12.

Chen J, Zhang S, Cui P, Shi W, Zhang W, Zhang Y . Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017; 72(12):3272-3276. PMC: 5890659. DOI: 10.1093/jac/dkx316. View

13.

Dorman S, Nahid P, Kurbatova E, Phillips P, Bryant K, Dooley K . Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021; 384(18):1705-1718. PMC: 8282329. DOI: 10.1056/NEJMoa2033400. View

14.

Hwang T, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K . Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014; 4(1):e004143. PMC: 3902362. DOI: 10.1136/bmjopen-2013-004143. View

15.

Dooley K, Luetkemeyer A, Park J, Allen R, Cramer Y, Murray S . Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014; 58(9):5245-52. PMC: 4135849. DOI: 10.1128/AAC.03332-14. View

16.

Lees A . Ethionamide, 750 mg. daily, plus isoniazid, 450 mg. daily, in previously untreated cases of pulmonary tuberculosis. Am Rev Respir Dis. 1965; 92(6):966-9. DOI: 10.1164/arrd.1965.92.6P1.966. View

17.

Swash M, Roberts A, Murnaghan D . Reversible pellagra-like encephalopathy with ethionamide and cycloserine. Tubercle. 1972; 53(2):132-6. DOI: 10.1016/0041-3879(72)90030-x. View

18.

Mukherjee T, Boshoff H . Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem. 2011; 3(11):1427-54. PMC: 3225966. DOI: 10.4155/fmc.11.90. View

19.

Caminero J, Garcia-Basteiro A, Rendon A, Piubello A, Pontali E, Migliori G . The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines. Eur Respir J. 2019; 54(4). DOI: 10.1183/13993003.01272-2019. View

20.

Shaw K, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar C . In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008; 52(12):4442-7. PMC: 2592863. DOI: 10.1128/AAC.00859-08. View